Celgene Corporation

  CELG website
  • We are currently testing fixes to the following bugs: Ignores, Inbox Folder Access, Hide Replies, View Thread & a few others. It's taking a little longer than we had hoped, but we expect to push out corrected code this Friday night. We apologize for the delay & appreciate your continued patience. Stay tuned for further updates.
Links:  Y!  RB   fly   AmericanBulls-CELG   The Myeloma Beacon   CELG Shareholders   SEC Petition to stop naked short selling   StockHub   How to deal with illegal short selling   Celgene Roulette 2013   General Biotech Discussion Board  
User Pass

CELG   /  Message Board

 
BOARD

GROUPS

NEWS
 








Big Jack
x
JRPetermann
x
kokope11i_om
x
laserluver
x
pharman2080
x
short_it_all
x


 
Loading...
 
 
--




My CELG Ignore List


Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous 1898 Messages Top of Message List
Go to Msg #  
MSG # SUBJECT TYPE AUTHOR SENTIMENT RECS DATE POSTED
177772 MRK is following Celgene: $5 B accelerated share repurchase; stock up sharply today. eom. GN teflon2000 5/21/2013 5:13:33 PM
177771 These findings suggest that AZA might be a potentially effective strategy for relapse of high risk myeloid malignancies post allo-HSCT, without unexpected toxicities or de novo GVHD GN Rob Cos 3 5/21/2013 4:07:39 PM
177770 AML patients treated with AZA (Vidaza) do better clinically than those patients who physicians elect to treat with DEC (Dacogen) based on statistically significant longer OS and fewer hospitalizations GN Rob Cos 3 5/21/2013 4:06:09 PM
177769 PROLONGED OVERALL SURVIVAL WITH POMALIDOMIDE AND DEXAMETHASONE IN END STAGE MYELOMA GN Rob Cos 3 5/21/2013 4:02:59 PM
177768 POM has shown activity in MM pts refractory to LEN/BORT. POM + LoDEX significantly extended PFS & OS vs. HiDEX + improvements in clinically relevant QOL measurements over course of Tx. POM + LoDEX should become a standard of care in these pts GN Rob Cos 2 5/21/2013 4:01:53 PM
177767 POM with or without LoDEX was effective and generally well tolerated in heavily pretreated RRMM patients who had already received LEN and BORT, including patients who had progressed on prior LEN. In general, age had no impact on overall response rate... GN Rob Cos 2 5/21/2013 3:59:13 PM
177766 POM with or without LoDEX represents a new clinical option for pts with advanced RRMM, including pts with LEN and BORT refractory disease. AEs were predictable and manageable. Updated data with extended follow-up will be presented at the meeting. GN Rob Cos 2 5/21/2013 3:58:11 PM
177765 Lenalidomide as initial therapy of elderly pts with CLL induced responses that are durable, with 57% of pts maintaining their response for more than 3 years GN Rob Cos 4 5/21/2013 3:56:56 PM
177764 Combination CRd therapy followed by extended LEN dosing in newly diagnosed MM patients show deep response rates corroborated by MRD assays and tolerable side effects. GN Rob Cos 2 5/21/2013 3:55:48 PM
177763 Relapsed/refractory MCL pts showed a consistent and predictable safety profile among 3 phase II studies of single-agent lenalidomide. The response to lenalidomide was rapid and durable in heavily pretreated pts, including pts who received prior bortezomib GN Rob Cos 2 5/21/2013 3:54:31 PM
177762 LOW-DOSE LENALIDOMIDE PLUS LOW DOSE CYTARABINE INDUCE COMPLETE REMISSION THAT CAN BE PREDICTED BY GENETIC PROFILING IN VERY ELDERLY ACUTE MYELOID LEUKEMIA PATIENTS. GN Rob Cos 3 5/21/2013 3:53:26 PM
177761 EHA EU post approval study in RRMM " Incidence of significant VTE was lower than observed in previous series. The incidence of SPM across all cohorts was 1%" (Remember MM-020 is Rev-dex no melphalan) GN Rob Cos 2 5/21/2013 3:51:53 PM
177760 EHA "With a still limited follow-up time, our data compare favorably with historical R-CHOP21 data. LR-CHOP21 is able to induce a high 2-yr PFS (73%) and it is effective also in poor risk patients (65%). The addition of lenalidomide to R-CHOP21 is safe wi GN Rob Cos 3 5/21/2013 3:49:13 PM
177759 Oral EHA abs "Single-agent lenalidomide treatment showed rapid and durable responses in heavily pretreated pts with MCL who were relapsed/refractory to bortezomib. The PK profile of lenalidomide in MCL pts was comparable to that in other patient populatio GN Rob Cos 4 5/21/2013 3:47:30 PM
177758 EHA18ABSSUB-3519 - SPM issue MAINLY with combo with melphalan.... observed survival benefit, the benefit/risk profile of lenalidomide treatment remains positive. GN Rob Cos 4 5/21/2013 3:46:11 PM
177757 EHA abstracts out - "CRd was well tolerated and highly active and provided robust and durable responses in patients with relapsed or progressive MM where 35% were lenalidomide refractory" GN Rob Cos 5 5/21/2013 3:42:58 PM
177756 Reminder from Feb - Citi says good MM-020 data/front line EU approval could add anywhere from $3.31 to $7.71 INCREMENTAL EPS...there's that OPERATING/EPS LEVERAGE ON INTERNATIONAL & INDICATION EXPANSION thing I have been posting about for yrs..... GN Rob Cos 6 5/21/2013 3:34:56 PM
177755 Re: Focus more on Dr Fouse's comments on why she will continue to buy back shrs..she thinks they're cheap....she is highly confident in MM-020 & Watson nuisance IP claim, & knows every P&L lever is going her way...."very unique position"... GN Celgeneistheone Strong Buy 4 5/21/2013 2:30:03 PM
177754 Re: BERNSTEIN "* Quick Take - Biotech Chart of the Week: Behcet's Disease - An Important Emerging Market Indication for Apremilast? Reiterate Outperform and $145 target" GN buygene 1 5/21/2013 12:55:36 PM
177753 BERNSTEIN "* Quick Take - Biotech Chart of the Week: Behcet's Disease - An Important Emerging Market Indication for Apremilast? Reiterate Outperform and $145 target" GN Rob Cos 8 5/21/2013 12:43:24 PM
Previous 1898 Messages Top of Message List
Go to Msg #  


About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help  •  Advertise
Not a member yet? What are you waiting for? Join Now
Want to contribute? Support InvestorVillage by donating
© 2003-2013 Investorvillage.com. All rights reserved. User Agreement 		   
Financial Market Data provided by
.


Loading...